Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
Ethan S LindgrenRongshan YanOnur CilAlan S VerkmanMatilda F ChanGerami D SeitzmanAsim V FarooqLaura A HuppertHope S RugoPaula R PohlmannJanice LuLaura J EssermanNeel D PasrichaPublished in: Current ophthalmology reports (2024)
Three of 11 FDA-approved ADCs have been implicated with corneal pseudomicrocysts, with incidence ranging from 41 to 100% of patients. Of the six ADCs that reported ocular surface AEs, only three had ocular substudies to investigate the benefit of preventive therapies including topical steroids, vasoconstrictors, and preservative-free lubricants. Current preventive therapies demonstrate limited efficacy at mitigating pseudomicrocysts and other ocular surface AEs.